The incidence and treatment of prostate cancer in male renal-transplant patients has not been extensively evaluated. With the aging of the renal-transplant population, the diagnosis and management of prostate cancer in these patients needs further evaluation.
In this study, we conducted a retrospective review of data from 498 male renal-transplant patients to evaluate the prevalence, treatment, and outcome of prostate cancer in this population.
Of the 498 male renal-transplant patients, nine were diagnosed with prostate cancer. A prostate specific antigen (PSA) screening program was not utilized, and these patients were diagnosed based on a prostate digital rectal examination and/or elevated PSA. The median age at transplantation was 55 years, and the median age at the diagnosis of prostate cancer was 63.6 years. One patient was treated with androgen ablation alone, four patients were with radiation alone, and four patients were treated with a combination of androgen ablation and external radiation. Twelve skin malignancies occurred in five of the patients with prostate cancer. Our patient population was preferentially treated with radiation therapy rather than radical prostatectomy. Seven of these treated patients are currently being followed and have good control of the disease. Two of the seven patients are on dialysis because of chronic allograft nephropathy. One patient was lost to follow-up, and one died with extensive metastasis, paraplegia, and renal failure.
The incidence of diagnosed prostate cancer in patients with renal transplant will increase because of systematic PSA screening. The recommended current treatment modality depends on the Gleason grade, stage, PSA levels, and associated comorbid conditions. A combination of radiation treatment with androgen ablation provides good control of the disease while preserving renal function.
This is a preview of subscription content, log in to check access.
Buy single article
Instant access to the full article PDF.
Price includes VAT for USA
Subscribe to journal
Immediate online access to all issues from 2019. Subscription will auto renew annually.
This is the net price. Taxes to be calculated in checkout.
Hafron J, Fogarty J, Wiesen A, Melman A (2005) Surgery for localized cancer of prostate. BJU Int 95:319–322
Penn I (2000) Post-transplant malignancy: the role of immunosuppression. Drug Saf 23:101–113
Diller R, Gruber A, Wolters H, Senninger N, Spiegel HU (2005) Therapy and prognosis of tumors of the genitourinary tract after kidney transplantation. Transplant Proc 37:2089–2092
Cormier L, Lechevallier E, Barrou B, Benoit G, Bensadoun H, Boudjema K, Descottes JL, Doré B, Guy L, Malavaud B, Martin X, Patard JJ, Petit J, Salomon L (2003) Diagnosis and treatment of prostate cancers in renal transplant recipients. Transplantation 75:237–239
Malavaud B, Hoff M, Meidouge M, Rostaing L (2000) PSA-based screening for prostate cancer after renal transplant. Transplantation 69:2461–2462
Sheil AGR (1999) Patterns of malignancies following renal transplantation. Transplant Proc 31:1263–1265
Gupta AK, Cardella C, Haberman HF (1986) Cutaneous malignant neoplasms in patients with renal transplant. Arch Dermatol 122:1288–1293
Hartevelt MM, Bavinck B, Kootte JN, Vermeer BJ, Vandenbroucke JP (1990) Incidence of skin cancer after transplantation in The Netherlands. Transplantation 49:506–509
Leibovitz A, Baumoehl Y, Segal R (2004) Increased incidence of pathological and clinical prostate cancer with age: age related alterations of local immune surveillance. J Urol 172:435–437
Mohammadi S, Silvaggio G, Bonnet N, Berberian G, Dorent R, Bikter M, Pavie A, Gandjbakhch I (2005) Prostate cancer after heart transplantation: unicenter case-control study. J Heart Lung Transplant 24:995–997
Konety BR, Tewari A, Howard RJ, Barry JM, Hodge EE, Taylor R, Jordan ML (1998) Prostate cancer in post transplantation population. Urology 52:428–432
Birkeland SA, Storm HH, Lamm LU, Birkeland SA, Storm HH, Lamm LU, Barlow L, Blohmé I, Forsberg B, Eklund B, Fjeldborg O, Friedberg M, Frödin L (1995) Cancer risk after transplantation in Nordic countries, 1964–86. Int J Cancer 60:183–189
Luan FL, Hojo M, Maluccio M, Yamaji K, Suthanthiran M (2002) Rapamycin blocks tumour progression; unlinking immunosuppression from antitumour efficacy. Transplantation 73:1565–1572
Yiou R, Salomon L, Colombel M, Patard JJ, Chopin D, Abbou CC (1999) Perineal approach to radical prostatectomy in kidney transplant recipients with localized prostate cancer. Urology 53:822–824
Shah KK, Ko DS, Mercer J, Dahl DM (2006) Laparoscopic radical prostatectomy in a renal allograft recipient. Urology 68:672.e5–672.e7
Thomas AA, Nguyen MM, Gill IS (2008) Laparoscopic transperitoneal radical prostatectomy in renal transplant recipients: a review of three cases. Urology 71:205–208
Maestro MA, Gómez AT, Alonso Y, Gregorio S, Ledo JC, de la Peña Barthel J, Martínez-Piñeiro L (2010) Laparoscopic transperitoneal radical prostatectomy in renal transplant recipients: a review of the literature. BJU Int 105:844–848
Mouzin M, Bechuad JM, Kamar N, Gamé X, Vaessen C, Rischmann P, Rostaing L, Malavaud B (2004) Three dimensional conformal radiotherapy for localised prostate cancer in kidney transplant recipients. Transplantation 78:1496–1500
About this article
Cite this article
Binsaleh, S. Diagnosis and treatment of prostate cancer in renal-transplant recipients. Int Urol Nephrol 44, 149–155 (2012). https://doi.org/10.1007/s11255-011-9988-8
- Prostate cancer
- Renal transplant
- PSA screening